<DOC>
	<DOCNO>NCT00085059</DOCNO>
	<brief_summary>RATIONALE : Boron neutron capture therapy use boronophenylalanine-fructose complex may kill tumor cell without harm normal tissue . PURPOSE : This phase II trial study well boron neutron capture therapy use boronophenylalanine-fructose complex work treat patient metastatic melanoma .</brief_summary>
	<brief_title>Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine therapeutic activity efficacy boron neutron capture therapy use boronophenylalanine-fructose complex patient metastatic melanoma . - Determine objective local response patient treat regimen . Secondary - Determine overall survival patient treat regimen . - Determine duration local response time local progression patient treat regimen . - Determine dose-response relationship per-lesion level patient treated regimen . - Determine safety regimen patient . - Determine toxicity regimen patient . OUTLINE : This open-label study . Patients receive boronophenylalanine-fructose complex IV 90 minute follow boron neutron capture therapy day 1 2 . Patients follow 1 6 week every 8 week thereafter . In event disease progression , patient follow every 3 month survival . PROJECTED ACCRUAL : A total 16-24 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma Metastatic disease Brain metastasis , skin metastasis , soft tissue metastasis head neck extremity Accessible lesion ( ) boron neutron capture therapy ( BNCT ) No clear progression disease sit one intend treatment surgery and/or BNCT Measurable disease MRI within past 4 week Lesion ( ) ≥ 10 mm diameter Indication palliative radiotherapy intend deliver BNCT PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Neutrophil count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Hepatic Bilirubin ≤ 2.5 time upper limit normal ( ULN ) * Transaminases ≤ 2.5 time ULN* Alkaline phosphatase ≤ 2.5 time ULN* NOTE : *Unless due reversible reaction antiseizure medication Renal Creatinine ≤ 2.5 time ULN Blood urea nitrogen ≤ 2.5 time ULN Cardiovascular No congestive heart failure No newly diagnose unstable angina pectoris No uncontrolled arrhythmias No uncontrolled conduction defect No recent coronary artery disease No severe heart disease Pulmonary No severe pulmonary disease , include severe obstructive restrictive lung disease Other No history phenylketonuria No severe gastrointestinal disease No active peptic ulcer disease No uncontrolled endocrine disease No preexist serious mental organic brain disease ( e.g. , epilepsy ) No psychological , familial , sociological , geographical condition would preclude study compliance Able travel Netherlands via public transportation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunologic biologic therapy No concurrent colonystimulating factor ( e.g. , epoetin alfa filgrastim [ GCSF ] ) Chemotherapy No concurrent chemotherapy Endocrine therapy No concurrent hormonal therapy Radiotherapy No prior radiotherapy site ( ) propose study treatment No concurrent radiotherapy Surgery See Disease Characteristics Other Recovered prior antitumor therapy ( exclude alopecia sensitive peripheral neuropathy ≤ grade 2 ) No concurrent anticancer therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>